Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 7/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ITGAV | P06756 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5155939 | 0.77 | ITGB3 (0.41) | ITGB3ITGA2BMAPTHPGDITGAV | |
| SCHEMBL7544674 | 0.74 | ITGB3 (0.39) | ITGB3ITGA2BMAPTHPGDITGAV | |
| SCHEMBL7366878 | 0.74 | ITGB3 (0.38) | ITGB3ITGA2BMAPTHPGDITGAV | |
| SCHEMBL4024554 | 0.70 | ITGB3 (0.58) | ITGB3ITGA2BITGAV | |
| SCHEMBL6948601 | 0.66 | ITGB3 (0.61) | ITGB3ITGA2BITGAV | |
| SCHEMBL6676170 | 0.66 | ITGB3 (0.56) | ITGB3ITGA2BITGAV | |
| SCHEMBL6676168 | 0.66 | ITGB3 (0.56) | ITGB3ITGA2BITGAV | |
| SCHEMBL6948600 | 0.66 | ITGB3 (0.61) | ITGB3ITGA2BITGAV | |
| SCHEMBL7798122 | 0.66 | HSD17B3 (0.39) | ITGB3ITGA2BMAPTHPGDITGAV | |
| SCHEMBL4024521 | 0.65 | ITGB3 (0.47) | ITGB3ITGA2BITGAVBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6765005-B2 | BACTERICIDES; ENZYME INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2004-07-20 | — | — | US | disclosed |
| US-20030139377-A1 | Fab I inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139377-A1 | Fab I inhibitors | SERPINB1, TFPI, TFPI2 | ITGB3 1680/4885ITGA2B 1135/4885MAPT 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.